What is LH's current stock price?

As of now, LH is trading at $284.00, with a daily change of +0.43%.

What are the risks associated with LH stock?

LH Key risk is its Low Risk Level, .

What is LH next earnings date?

LH next earnings report is scheduled for Oct 23, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

LH Stock Analysis & IQ Rating | Laboratory Corporati

LH

Laboratory Corporati

$284.00

+$1.16 | +0.43%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 293.72

MKT CAP

$ 23.60B

52W Low

$ 209.38

VOL

$ 519.95K

P/E Ratio

31.31

AVG VOL

$ 513.82K

RSI

58.31

TREND

Sideways

LH Stock IQ

Login to see Laboratory Corporati (LH) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

LH Target Price

Login to display

Not Enough Information

Strengths

LH Rewards

Earnings are forecast to grow

LH Rewards

Trading below its fair value

Chart

$282.75 (+0.44%)

$263.48 (+7.79%)

$255.88 (+10.99%)

$246.31 (+15.30%)

1year

6month

3month

1month

LH Risk Level

LH has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

LH Analysts Opinion

LH overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

LH Analysts Opinion

LH Analysts opinion is negative and it remained unchanged from the past 3 months

LH Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

91%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

92%

LH Street Opinion

LH Street view is extremely bullish and have negative views on the near-term outlook

LH Performance Sentiment

Sentiments overview associated with LH events and the stock performance.

91%

0%

Positive

Negative

10 out of 11
events present

0 out of 11
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

LH Earnings

The TTM reflects 12-month period, providing review of LH financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

13,484

13,009

12,162

+5.29%

Cost of Revenue

9,689

9,385

8,797

+4.95%

Gross Profit

3,795

3,624

3,365

+6.20%

Operating Exp

2,561

2,486

2,241

+6.90%

Operating Inc

1,234

1,138

1,124

+4.78%

Net Interest Inc

-227

-208

-200

-

Interest Exp

227

208

200

+6.54%

Other Inc Exp

-33

30

-355

-

EPS Growth

9.14

8.89

4.80

+37.99%

LH Financial Health

The company financial health has moderately improved over the past year

Financial Score

3.62

Next Earnings Date: Oct 23, 2025

Linked to LH

IQ

Close Price

Change

EXAS

4.12

64.85

+3.08%

GH

3.69

69.35

+1.94%

DGX

4.14

183.23

+1.11%

LH Latest Analysis +

Ramaco Breaks Ground on Pilot Processing Plant and Lab to Advance Rare Earth and Critical Mineral Development. METCB)) (".Ramaco". or the ".Company".) Ramaco is proud to announce that initial mobilization and site development activities have commenced for its new pilot processing plant and laboratory located adjacent to the Brook Mine and near the iCAM Research Center outside The facility is designed to demonstrate the technical and economic feasibility of converting domestic carbon

Today

$284.00 | +0.43%

Activity

Avantor® Announces Partnership with p-Chip Corporation to Develop Solutions for Digital Traceability of Smart Consumables. New product line will enable secure chain-of-identity enhanced traceability and digital process control in pharmaceutical and clinical workflows – supporting the growing demand for individualized therapies) a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries today announced a collaboration a

Today

$284.00 | +0.43%

Activity

Labcorp Declares Quarterly Dividend. (NYSE:) a global leader of innovative and comprehensive laboratory services announced today that its Board of Directors has declared a cash dividend of ...

Wed Oct 8, 2025

$277.51 | -0.73%

Activity

Baylor Genetics to Showcase Clinical and Diagnostic Utility of Genome Sequencing and Multi-omics Across Rare Disease at the American Society of Human Genetics 2025 Annual Meeting. HOUSTON Oct. 08 2025 (GLOBE NEWSWIRE) -- a clinical diagnostic laboratory at the forefront of genetic testing today announced it will showcase its leadership in genome sequencing and multi-omics to uncover critical information leading to rare disease diagnoses through eight poster presentations at the taking place Oc

Wed Oct 8, 2025

$277.51 | -0.73%

Activity

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer. NEW YORK Oct. 08 2025 (GLOBE NEWSWIRE) -- Nilo Therapeutics a biotechnology company harnessing neural circuits to restore immune homeostasis in disease launched today with a $101 million Series A financing led by The Column Group (TCG) DCVC Bio and Lux Capital with participation from the Gates Foundation

Wed Oct 8, 2025

$277.51 | -0.73%

Activity

Hunting Parasites to Save Animal Lives - From the Deep Sea to the Family Dog: MiDOG Expands Veterinary Genomics with First Set of Parasite Reference Genomes in Collaboration with the University of Nebraskas Harold W. Manter Laboratory of Parasitology. TUSTIN Calif. Oct. 8 2025 /PRNewswire/ -- MiDOG Animal Diagnostics has released its first set of parasite reference genomes for companion animals and wildlife publicly available through the National Center for Biotechnology Information (NCBI). This

Wed Oct 8, 2025

$277.51 | -0.73%

Activity

FAQ About LH Stock Insights

What is LH current stock price?

What are LH stock strengths?

What risks are associated with LH stock?

When is LH next earnings report?

What is LH market cap and volume?

What is LH's current Stock IQ?

Should I buy LH stock right now?

Is LH a Strong Buy right now?

What does a 'Strong Buy' rating mean for LH?

What does a 'Strong Sell' rating mean for LH?

What factors influence LH's Stock IQ?

Explore our LH Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored LH Stock Strategies
Effective Risk Management

FIND US ON

Receive our LH Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

LH

Laboratory Corporati

Current Price

$284.00

+$1.16 | +0.43%

52W High

$ 293.72

MKT CAP

$ 23.60B

52W Low

$ 209.38

VOL

$ 519.95K

P/E Ratio

31.31

AVG VOL

$ 513.82K

RSI

58.31

TREND

Sideways

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

LH Rewards

Earnings are forecast to grow

LH Rewards

Trading below its fair value

Linked to LH

Symbol

IQ

Close

Change

EXAS

4.12

64.85

+3.08%

GH

3.69

69.35

+1.94%

DGX

4.14

183.23

+1.11%

LH Stock IQ

Login to unlock Laboratory Corporati (LH) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$282.75 (+0.44%)

$263.48 (+7.79%)

$255.88 (+10.99%)

$246.31 (+15.30%)

1year

6month

3month

1month

LH Analysts Opinion

LH Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

LH Analysts Opinion

LH Analysts opinion is negative and it remained unchanged from the past 3 months

LH Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

91%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

92%

LH Street Opinion

LH Street view is extremely bullish and have negative views on the near-term outlook

LH Risk Level

LH has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

LH Performance Sentiment

Sentiments overview associated with LH events and the stock performance.

91%

0%

Positive

Negative

10 out of 11
events present

0 out of 11
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

LH Earnings

The TTM data reflects the most recent 12-month period, providing overview of LH financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

13,484

13,009

12,162

+5.29%

Cost of Revenue

9,689

9,385

8,797

+4.95%

Gross Profit

3,795

3,624

3,365

+6.20%

Operating Exp

2,561

2,486

2,241

+6.90%

Operating Inc

1,234

1,138

1,124

+4.78%

Net Interest Inc

-227

-208

-200

-

Interest Exp

227

208

200

+6.54%

Other Inc Exp

-33

30

-355

-

EPS Growth

9.14

8.89

4.80

+37.99%

LH Financial Health

The company financial health has moderately improved over the past year

Financial Score

3.62

Next Earnings Date: Oct 23, 2025

LH Latest Analysis

Ramaco Breaks Ground on Pilot Processing Plant and Lab to Advance Rare Earth and Critical Mineral Development. METCB)) (".Ramaco". or the ".Company".) Ramaco is proud to announce that initial mobilization and site development activities have commenced for its new pilot processing plant and laboratory located adjacent to the Brook Mine and near the iCAM Research Center outside The facility is designed to demonstrate the technical and economic feasibility of converting domestic carbon

Today

$284.00 | +0.43%

Activity

Avantor® Announces Partnership with p-Chip Corporation to Develop Solutions for Digital Traceability of Smart Consumables. New product line will enable secure chain-of-identity enhanced traceability and digital process control in pharmaceutical and clinical workflows – supporting the growing demand for individualized therapies) a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries today announced a collaboration a

Today

$284.00 | +0.43%

Activity

Labcorp Declares Quarterly Dividend. (NYSE:) a global leader of innovative and comprehensive laboratory services announced today that its Board of Directors has declared a cash dividend of ...

Wed Oct 8, 2025

$277.51 | -0.73%

Activity

Baylor Genetics to Showcase Clinical and Diagnostic Utility of Genome Sequencing and Multi-omics Across Rare Disease at the American Society of Human Genetics 2025 Annual Meeting. HOUSTON Oct. 08 2025 (GLOBE NEWSWIRE) -- a clinical diagnostic laboratory at the forefront of genetic testing today announced it will showcase its leadership in genome sequencing and multi-omics to uncover critical information leading to rare disease diagnoses through eight poster presentations at the taking place Oc

Wed Oct 8, 2025

$277.51 | -0.73%

Activity

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer. NEW YORK Oct. 08 2025 (GLOBE NEWSWIRE) -- Nilo Therapeutics a biotechnology company harnessing neural circuits to restore immune homeostasis in disease launched today with a $101 million Series A financing led by The Column Group (TCG) DCVC Bio and Lux Capital with participation from the Gates Foundation

Wed Oct 8, 2025

$277.51 | -0.73%

Activity

Hunting Parasites to Save Animal Lives - From the Deep Sea to the Family Dog: MiDOG Expands Veterinary Genomics with First Set of Parasite Reference Genomes in Collaboration with the University of Nebraskas Harold W. Manter Laboratory of Parasitology. TUSTIN Calif. Oct. 8 2025 /PRNewswire/ -- MiDOG Animal Diagnostics has released its first set of parasite reference genomes for companion animals and wildlife publicly available through the National Center for Biotechnology Information (NCBI). This

Wed Oct 8, 2025

$277.51 | -0.73%

Activity

Discover LH Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of LH. We're here to help you make informed investment decisions today.

FIND US ON

Receive our LH Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

LH Stock trends

LH Stock performance

LH Stock analysis

LH investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing LH

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing LH

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

LH Stock Analysis & IQ Rating | Laboratory Corporati

LH Stock IQ

LH Target Price

LH Risk Level

LH Analysts Opinion

LH Street Consensus

LH Performance Sentiment

LH Financial Health

Explore our LH Stock insights

Receive our LH Daily Alerts

LH Stock IQ

LH Street Consensus

LH Risk Level

Discover LH Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of LH. We're here to help you make informed investment decisions today.

Receive our LH Daily Alerts

LH Runner Alarm